• Rongsu Technology

  Led · Series A · Mar 2026

  Founded in 2020, Rongsu Technology develops and sells DED (directed energy deposition) multi-laser wire-feed metal 3D printing systems and provides printing, equipment, and component services. Its technology roadmap moved from arc-based WAAM toward laser wire-feed (WLAM) and includes proprietary multi-laser coaxial wire-feed VEAM to improve accuracy and stability at high speeds; its Robo L1 and STAR series have won orders from major aerospace and heavy-industry customers. The company recently launched the Laser Mini desktop multi-laser wire-feed metal printer to address scientific and educational users. Equipment sales currently account for the largest share of revenue, though Rongsu expects printing services to become the main revenue driver as delivery capacity increases. Rongsu reported tens of millions of yuan in revenue in 2025 and expects revenue to double in 2026. It plans a Suzhou service-base project with planned investment over ¥500 million and projected annual revenue over ¥300 million at full capacity.

• Stilla Technologies

  Participated · Series C · Mar 2024

  Stilla Technologies builds digital PCR instruments and consumables based on its Crystal Digital PCR technology, including the Nio™ platform and the recent Nio™+ 7‑color system. The Nio™+ can detect 20+ biomarkers per assay, offering a 3–4x multiplexing advantage over competitors and sitting between qPCR and NGS on cost and data density. Stilla positions its systems to fit laboratory workflows, emphasizing ease of use and automation compatibility (e.g., the Ruby Chip). The company targets applications across cancer/liquid biopsy, cell and gene therapy, infectious disease diagnostics and monitoring, epidemiology, food and environmental testing. Over 10 years of product development includes a 3‑color system in 2016, a 6‑color system in 2021, the automation‑ready Ruby Chip in 2022, and the November launch of Nio™+. Financially, Stilla closed a €26.5M Series C and employs over 80 people. Leadership and board changes were made recently following the CEO's reappointment in October, and the company cites expanded executive and board teams as part of its next chapter. Stilla Technologies develops multiplex Crystal Digital PCR solutions, most notably the naica® system—the industry's first six‑color digital PCR platform. The company targets applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla recently launched the six‑color naica® system, which it says is in high demand among researchers and clinicians. The company plans to use new financing to expand its global commercial presence and to develop its next‑generation digital PCR platform. Stilla has U.S. headquarters in Boston and European headquarters in Paris, and maintains strategic distribution and business partnerships in China. Financially, Stilla secured €31.3 million in the form of €11.3 million of convertible bonds and €20 million in loan financing. Stilla Technologies develops the Naica System, a digital PCR platform that enables precise detection and quantification of DNA mutations for research organizations in molecular biology and genetic analysis. The company was founded in 2013 at Ecole Polytechnique by Rémi Dangla, its CEO. Stilla launched the first generation of the Naica System in 2016 and generated first revenues in 2017. The Series B proceeds will be used to boost development of its solution, with a focus on high analytical performance and adding 6-color detection capabilities. The company positions its product for research organizations requiring high-precision genetic analysis. Stilla Technologies is a Paris-based life sciences company that provides a flexible digital PCR (dPCR) solution, the Naica System, for next-generation genetic tests. Founded in 2013 at École Polytechnique and led by CEO Rémi Dangla, the company leverages microfluidic innovations to make dPCR a lab commodity across the life sciences. Its core product is the Naica System; Stilla plans to launch a second-generation solution and to begin clinically validating panels to run on the system, initially focusing on oncology. The company intends to use new funding to accelerate Naica sales and expand clinical validation efforts. No operating metrics were disclosed in the article.

No current team members are available.